LCNDG Rapid Review: Brentuximab vedotin for Hodgkin's lymphoma

Source: London Cancer New Drugs Group Area: Evidence > Drug Specific Reviews Due to the rarity of the condition and the licensing of brentuximab vedotin, randomised control trials are now unlikely to be conducted for brentuximab vedotin in this indication.   The best available data at this time come from a multinational Phase II study (n=102) that found brentuximab vedotin to be associated with an objective response rate of 75%, with a complete remission seen in 34%.  At the time of the analysis, the median duration of response for those in complete remission was 20.5 months and the estimated 12-month survival was 89%. The US and UK licence for brentuximab vedotin for Hodgkin's lymphoma was based on the results of this phase II trial.   The phase II clinical trial included patients who had received prior ASCT. The licensed indication also states that brentuximab vedotin is indicated for relapsed or refractory HL following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option. These patients ...
Source: NeLM - Drug Specific Reviews - Category: Drugs & Pharmacology Source Type: news